Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

SIMPLE SUMMARY: Acquiring of resistance is a common outcome after prolonged cancer treatment and consecutive treatments are, in general terms, limited. Here we published the results of REVERT clinical study that aimed to REVERT the resistance to hormonal treatment that often occurs in breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: López González, Ana, Del Barco Berrón, Sonia, Grau, Isabel, Galan, Maria, Castelo Fernández, Beatriz, Cortés, Alfonso, Sánchez Rovira, Pedro, Martinez-Bueno, Alejandro, Gonzalez, Xavier, García, Almudena, Gener, Petra, Mina, Leonardo, Alcalá-López, Daniel, Sampayo, Miguel, Cortés, Javier, Pérez-Garcia, José Manuel, Llombart-Cussac, Antonio, López-Miranda, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737152/
https://www.ncbi.nlm.nih.gov/pubmed/36497361
http://dx.doi.org/10.3390/cancers14235880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737152/
https://www.ncbi.nlm.nih.gov/pubmed/36497361
http://dx.doi.org/10.3390/cancers14235880

Ejemplares similares